[1] Torre LA, Siegel RL, Ward EM, et al. Global cancer incidence and mortalityrates and trends--an update[J].Cancer Epidemiol Biomarkers Prev,2016,25(1):16-27.
[2] Han XM, Zheng KW, Wang RL, et al. Functionalization and optimization-strategy of graphene oxide-based nanomaterials for gene and drug delivery[J].Am J Transl Res,2020,12(5):1515-1534.
[3] Yousefnia S.Mechanistic effects of arsenic trioxide on acute promyelocytic leukemia and other types of leukemias[J].Cell Biol Int,2021,45(6):1148-1157.
[4] Chen YJ, Huang CH, Shi YJ, et al. The suppressive effect of arsenic trioxide on TET2-FOXP3-Lyn-Akt axis-modulated MCL1 expression induces apoptosis in human leukemia cells[J].Toxicol Appl Pharmacol,2018,358:43-55.
[5] Lang W, Zhu J, Chen F, et al. EVI-1 modulates arsenic trioxide induced apoptosis through JNK signalling pathway in leukemia cells[J].Exp Cell Res,2019,374(1):140-151.
[6] Hassani S, Khaleghian A, Ahmadian S, et al. Redistribution of cell cycle by arsenic trioxide is associated with demethylation and expression changes of cell cycle related genes in acute promyelocytic leukemia cell line (NB4)[J].Ann Hematol,2018,97(1):83-93.
[7] Guo M, Zhou J, Fan S, et al. Characteristics and clinical influence factors of arsenic species in plasma and their role of arsenic species as predictors for clinical efficacy in acute promyelocytic leukemia (APL) patients treated with arsenic trioxide[J].Expert Rev Clin Pharmacol,2021,14(4):503-512.
[8] Liu XJ, Wang LN, Zhang ZH, et al. Arsenic trioxide induces autophagic degradation of the FLT3-ITD mutated protein in FLT3-ITD acute myeloid leukemiacells[J].J Cancer,2020,11(12):3476-3482.
[9] Li T, Ma R, Zhang Y, et al. Arsenic trioxide promoting ETosis in acute promyelocytic leukemia through mTOR-regulated autophagy[J].Cell Death Dis,2018,9(2):75.
[10] Xu W, Li X, Quan L, et al. Arsenic trioxide decreases the amount and inhibits the function of regulatory T cells, which may contribute to its efficacy in the treatment of acute promyelocytic leukemia[J].Leuk Lymphoma,2018,59(3):650-659.
[11] Masciarelli S, Capuano E, Ottone T, et al. Retinoic acid and arsenic trioxide sensitize acute promyelocytic leukemia cells to ER stress[J].Leukemia,2018,32(2):285-294.
[12] Vineetha RC, Hariharan S, Jaleel A, et al. L-ascorbic acid and α-tocopherol synergistically triggers apoptosis inducing antileukemic effects of arsenic trioxide via oxidative stress in human acute promyelocytic leukemia cells[J].Front Oncol,2020,10:65.
[13] Mohammadi KM, Mohammadi S, Tavallaei M, et al. Inhibitory effects of arsenic trioxide and thalidomide on angiogenesis and vascular endothelial growth factor expression in leukemia cells[J].Asian Pac J Cancer Prev,2018,19(4):1127-1134.
[14] Kuo YJ, Liu YJ, Way TD, et al. Synergistic inhibition of leukemia WEHI-3 cell growth by arsenic trioxide and hedyotis diffusa willd extract in vitro and in vivo[J].Exp Ther Med,2017,13(6):3388-3396.
[15] Abbaszade DM, Soleimani M, Atashi A, et al. The effect of simultaneous administration of arsenic trioxide and microvesicles derived from human bone marrow mesenchymal stem cells on cell proliferation and apoptosis of acute myeloid leukemia cell line[J].Artif Cells Nanomed Biotechnol,2018,46(sup3):S138-S146.
[16] Tan M, Zhang Q, Yuan X, et al. Synergistic killing effects of homoharringtonine and arsenic trioxide on acute myeloid leukemia stem cells and the underlying mechanisms[J].J Exp Clin Cancer Res,2019,38(1):407.
[17] Kouhpaikar H, Sadeghian MH, Rafatpanah H, et al. Synergy between parthenolide and arsenic trioxide in adult T-cell leukemia/lymphoma cells in vitro[J].Iran J Basic Med Sci,2020,23(5):616-622.
[18] Esmaeili S, Safaroghli-Azar A, Pourbagheri-Sigaroodi A, et al. Activation of PPARγ intensified the effects of arsenic trioxide in acute promyelocytic leukemia through the suppression of PI3K/Akt pathway:Proposing a novel anticancer effect for pioglitazone[J].Int J Biochem Cell Biol,2020,122:105739.
[19] Salmon JM, Bots M, Vidacs E, et al. Correction to:Combining the differentiating effect of panobinostat with the apoptotic effect of arsenic trioxide leads to significant survival benefit in a model of t(8;21) acute myeloid leukemia[J].Clin Epigenetics,2020,12(1):178.
[20] Li SY, Lu Y, Liu HC, et al. Arsenic trioxide and all-trans retinoic acid in the treatment of children with newly diagnosed acute promyelocytic leukemia[J].Leuk Lymphoma,2021,62(5):1267-1270.
[21] Xu X, Mao Y, Zhu X, et al. Alternate application of all-trans-retinoic acid and arsenic trioxide combined with idarubicin/daunorubicin in treatment of acute promyelocytic leukemia[J].Pak J Pharm Sci,2022,35(1):23-28.
[22] Chen J, Tian B, Zhou C, et al. A novel resveratrol-arsenic trioxide combination treatment synergistically induces apoptosis of adriamycin-selected drug-resistant leukemia k562 cells[J].J Cancer,2019,10(22):5483-5493.
[23] Zabihi M, Safaroghli-Azar A, Gharehbaghian A, et al. CDK blockade using AT7519 suppresses acute myeloid leukemia cell survival through the inhibition of autophagy and intensifies the anti-leukemic effect of arsenic trioxide[J].Iran J Pharm Res,2019,18(Suppl1):119-131.
[24] Toosi B, Zaker F, Alikarami F, et al. VS-5584 as a PI3K/mTOR inhibitor enhances apoptotic effects of subtoxic dose arsenic trioxide via inhibition of NF-κB activity in B cell precursor-acute lymphoblastic leukemia[J].Biomed Pharmacother,2018,102:428-437.
[25] Jambrovics K, Uray IP, Keillor JW, et al. Benefits of combined all-trans retinoic acid and arsenic trioxide treatment of acute promyelocytic leukemia cells and further enhancement by inhibition of atypically expressed transglutaminase 2[J].Cancers(Basel),2020,12(3):648.
[26] Sayyadi M, Safaroghli-Azar A, Pourbagheri-Sigaroodi A, et al. c-Myc inhibition using 10058-F4 increased the sensitivity of acute promyelocytic leukemia cells to arsenic trioxide via blunting PI3K/NF-κB axis[J].Arch Med Res,2020,51(7):636-644.
[27] Hoang DH, Buettner R, Valerio M, et al. Arsenic trioxide and venetoclax synergize against AML progenitors by ROS induction and inhibition of Nrf2 activation[J].Int J Mol Sci,2022,23(12):6568.
[28] Fan J, He Q, Wang Z, et al. Self-assembled nanocomplex for co-delivery of arsenic-retinoic acid prodrug into acute promyelocytic leukemia cells[J].J Biomed Nanotechnol,2018,14(6):1052-1065.
[29] Fan L, Liu C, Hu A, et al. Dual oligopeptides modification mediates arsenic trioxide containing nanoparticles to eliminate primitive chronic myeloid leukemia cells inside bone marrow niches[J].Int J Pharm,2020,579:119179.
[30] Wang T, Wen T, Li H, et al. Arsenic sulfide nanoformulation induces erythroid differentiation in chronic myeloid leukemia cells through degradation of BCR-ABL[J].Int J Nanomedicine,2019,14:5581-5594.
